“…PET‐imaging is a powerful in vivo technique that uses selective and specific PET‐tracers to monitor specific proteins, their location and density as well as metabolic processes in the body (Fowler et al, 2005). Thanks to recent advances in the field of in vivo biomarkers, different types of PET‐tracers, CSF and plasma biomarkers are currently being used to track Aβ plaques, tau neurofibrillary tangles (NFTs), glucose metabolism, and neuroinflammatory processes (microglia and astrocytes activation) in AD and other proteinopathies (Nordberg, 2011, 2014; Perani et al, 2019; Rodriguez‐Vieitez & Nordberg, 2018; Saint‐Aubert et al, 2017). The recent approval of several new Aβ‐PET tracers in 2012 by the Food and Drug Administration (FDA), along with rapid progress in the development of tau‐tracers (Saint‐Aubert et al, 2017; Villemagne et al, 2018) and the FDA approval of first tau PET‐tracer flortaucipir or AV‐1451 (a radioactive diagnostic agent for the clinical PET‐imaging of NFTs in human brain (Jie et al, 2021)) in 2020, suggest that the field is moving rapidly.…”